Want to see CLPT full AI Analyst Report?
Top Page
ClearPoint Neuro
(NASDAQ:CLPT)
Select Model
Select Model
Rating:47Neutral
Price Target:
$10.50
▼(-38.09% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by weak financial performance (large losses, heavy cash burn, and increased leverage), reinforced by bearish technicals (price below key moving averages and negative MACD). Partially offsetting these risks are a more constructive earnings-call outlook with raised/defined revenue guidance and operational catalysts (CAL/GLP, partner momentum), though near-term cash management remains critical.
Positive Factors
Revenue growth and stable gross margins
Sustained revenue growth alongside stable gross margins indicates that ClearPoint is expanding its commercial base without sacrificing product economics. Continued scaling can strengthen operating leverage over time, support reinvestment in innovation, and improve the company’s ability to convert market adoption into future profitability.
Negative Factors
Persistent losses and high operating expense growth
Large operating losses show that revenue growth has not yet produced sufficient operating leverage. Elevated spending on research, sales, marketing, and administration may support expansion, but unless those investments generate proportionate revenue, losses can remain durable and delay the path to self-funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and stable gross margins
Sustained revenue growth alongside stable gross margins indicates that ClearPoint is expanding its commercial base without sacrificing product economics. Continued scaling can strengthen operating leverage over time, support reinvestment in innovation, and improve the company’s ability to convert market adoption into future profitability.
Read all positive factors
ClearPoint Neuro (CLPT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$332.34M
Dividend YieldN/A
Average Volume (3M)673.95K
Price to Earnings (P/E)―
Beta (1Y)1.76
Revenue Growth25.86%
EPS Growth-47.31%
CountryUS
Employees172
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.18
Shares Outstanding30,504,227
10 Day Avg. Volume911,681
30 Day Avg. Volume673,946
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)13.82
Price to Sales (P/S)10.48
P/FCF Ratio-15.84
Enterprise Value/Market Cap1.72
Enterprise Value/Revenue13.55
Enterprise Value/Gross Profit21.64
Enterprise Value/Ebitda-20.89
Forecast
1Y Price Target
$25.00Price Target Upside47.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$48.90M
ClearPoint Neuro Business Overview & Revenue Model
Company Description
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-ti...
How the Company Makes Money
ClearPoint Neuro makes money primarily by selling and supporting its MRI-guided neurosurgical platform and the procedure-linked products used with it. Key revenue streams typically include: (1) Capital equipment and software revenue from the sale ...
ClearPoint Neuro Earnings Call Summary
Earnings Call Date:Aug 03, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Positive
The call conveyed a largely constructive strategic and operational picture: top‑line growth (18% YoY), improved gross margin, successful product adoption (notably IRRAflow and updated navigation software), acquisition of the CAL facility with a signed GLP statement of work, and encouraging partner regulatory momentum. These positives are tempered by meaningful near‑term challenges — a sizable cash decline driven by a $15M operational burn through Q2, substantial increases in operating expenses, a 15% decline in biologics & drug delivery revenue in the quarter, and delayed GLP/preclinical revenue recognition into 2027. Management framed the expense increases as purposeful investments to capture accelerated partner launches and long‑term opportunity. On balance, the strategic catalysts and partner momentum appear to outweigh the near‑term financial pressures, though execution on timing and cash management will be critical.Positive Updates
Revenue and Margin Improvement
Total revenue of $10.9M in Q2 2026, up 18% year-over-year from $9.2M; gross margin improved to 62% from 60% (+2 percentage points). Capital equipment & software revenue increased 24% to $1.3M.
Negative Updates
Cash Decline and Operational Cash Burn
Cash and cash equivalents decreased to $29.4M as of June 30, 2026 from $45.9M at December 31, 2025. Management attributed the reduction primarily to $15M of operational cash burn through Q2 2026 plus ~$2M in tax payments tied to net share settlement of equity awards. Cash runway and burn remain key near‑term considerations.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue and Margin Improvement
Total revenue of $10.9M in Q2 2026, up 18% year-over-year from $9.2M; gross margin improved to 62% from 60% (+2 percentage points). Capital equipment & software revenue increased 24% to $1.3M.
Read all positive updates
Company Guidance
Management set 2026 revenue guidance of $48–52 million and said it will shift investment from traditional sales expansion to clinical case support, global regulatory expansion, CAL capital equipment and development of focused ultrasound, robotics and Harmony software. In Q2 FY2026 total revenue was $10.9M (up 18% vs $9.2M Q2 2025) comprised of biologics & drug delivery $4.0M (down 15% YoY), neurosurgery navigation $5.6M, and capital equipment & software $1.3M (up 24%); IRRAflow contributed $2.1M in disposables and ~$0.35M in equipment. Gross margin improved to 62% (vs 60% prior year); operating spend increased with R&D $4.6M (+21%), sales & marketing $6.8M (+68%) and G&A $5.6M (+64%); cash was $29.4M at June 30 (vs $45.9M at 12/31/25) after ~ $15M operational cash burn through Q2 plus $2M tax payments, and management expects burn to decrease in H2 as integrations complete. Key capacity milestones: possession of a 30,000 sq ft ClearPoint Advanced Laboratories, a signed multi‑million dollar GLP statement of work expected complete in H1 2027, plans to hire global clinical specialists (12–15 months to be fully ready), an expectation of 10–15 trials enrolling over the next 18 months, and modeled per‑patient revenue generally $12k–15k (uniQure procedures ~$15k–25k); 2027 growth is expected in the high‑teens to ~20% range but could accelerate if CAL/GLP execution or partner approvals proceed faster.ClearPoint Neuro Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.28M | 36.97M | 31.39M | 23.95M | 20.55M | 16.30M |
| Gross Profit | 26.47M | 22.69M | 19.12M | 13.61M | 13.53M | 11.12M |
| EBITDA | -27.42M | -20.86M | -17.01M | -20.63M | -15.58M | -12.74M |
| Net Income | -34.57M | -25.54M | -18.91M | -22.09M | -16.43M | -14.41M |
Balance Sheet | ||||||
| Total Assets | 86.74M | 97.75M | 39.19M | 42.66M | 55.49M | 65.58M |
| Cash, Cash Equivalents and Short-Term Investments | 29.36M | 45.92M | 20.10M | 23.14M | 37.49M | 54.11M |
| Total Debt | 63.95M | 58.23M | 3.57M | 13.94M | 11.99M | 12.28M |
| Total Liabilities | 75.97M | 69.73M | 13.80M | 21.49M | 18.60M | 16.79M |
| Stockholders Equity | 10.78M | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M |
Cash Flow | ||||||
| Free Cash Flow | -31.29M | -24.45M | -9.22M | -14.44M | -16.42M | -12.87M |
| Operating Cash Flow | -30.18M | -23.93M | -8.95M | -13.72M | -16.17M | -12.70M |
| Investing Cash Flow | 30.00K | 615.00K | -275.00K | 8.95M | -10.74M | -168.00K |
| Financing Cash Flow | 18.72M | 50.18M | 6.19M | 296.00K | 409.00K | 46.88M |
ClearPoint Neuro Technical Analysis
Negative
16.96
Price Trends
14.39
Negative
14.60
Negative
13.41
Negative
Market Momentum
-0.69
Positive
32.92
Neutral
5.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Negative. The current price of 16.96 is above the 20-day moving average (MA) of 13.62, above the 50-day MA of 14.39, and above the 200-day MA of 13.41, indicating a bearish trend. The MACD of -0.69 indicates Positive momentum. The RSI at 32.92 is Neutral, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLPT.
ClearPoint Neuro Risk Analysis
ClearPoint Neuro disclosed 57 risk factors in its most recent earnings report. ClearPoint Neuro reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ClearPoint Neuro Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.10B | 16.34 | 28.39% | ― | 3.14% | ― | |
59 Neutral | $810.32M | -53.21 | -8.23% | ― | 15.30% | 40.66% | |
55 Neutral | $370.26M | -5.92 | -14.05% | ― | 2.99% | 51.77% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $332.34M | -9.23 | -188.09% | ― | 25.86% | -47.31% |
* Healthcare Sector Average
CLPT
ClearPoint Neuro
10.90
-15.70
-59.03%
OFIX
Orthofix Medical
9.09
-5.08
-35.85%
SIBN
SI-Bone
18.08
3.59
24.78%
BVS
Bioventus
13.13
6.34
93.37%
ClearPoint Neuro Corporate Events
Business Operations and StrategyFinancial Disclosures
ClearPoint Neuro Updates Q2 Results and 2026 Outlook
Positive
Aug 3, 2026
On August 3, 2026, ClearPoint Neuro reported second quarter 2026 revenue of $10.9 million, up 18% year over year, driven by strong growth in neurosurgery navigation and therapy products and capital equipment, partially offset by a 15% decline in b...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.